Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A%230000613" target="_blank" >RIV/00209805:_____/15:#0000613 - isvavai.cz</a>
Result on the web
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376345/" target="_blank" >http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376345/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s12876-015-0266-6" target="_blank" >10.1186/s12876-015-0266-6</a>

Result language
angličtina
Original language name
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer
Original language description
The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS(wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We obs
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)